Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
VA New England Mental Illness, Research, Education and Clinical Center and Yale Department of Psychiatry, West Haven, CT, USA (США)
Список исп. литературыСкрыть список 1. Chue P, Eerdekens M, Augustyns I et al. Comparative efficacy and safety of long- acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005;15: 111-7. 2. Bai YM, Ting Chen T, Chen JY et al. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J Clin Psychiatry 2007;68:18-25. 3. Keks NA, Ingham M, Khan A et al. Long- acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open- label study. BrJ Psychiatry 2007;191:131-9. 4. Macfadden W, Ma Y, Haskins JT et al. A prospective study comparing the longterm effectiveness of injectable risperidone long-acting therapy and oral aripi- prazole in patients with schizophrenia. Psychiatry 2010; 7: 23-31. 5. Rosenheck RA, Krystal JH, Lew R et al. Risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med 2011;364:842-51. 6. Schooler NR, Buckley PF, Mintz J et al. PROACTIVE: Initial results of an RCT comparing long-acting injectable risperidone to 2nd generation oral antipsychotics. Presented at the 50th Annual Meeting of the American College of Neuropsychopharmacology, Kona, December 2011. 7. Gaebel W, Schreiner A, Bergmans P et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs. quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology 2010; 35:2367-77. 8. Kishimoto T, Robenzadeh A, Leucht C et al. Long-acting injectable vs. oral anti- psychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull (in press). 9. Fusar-Poli P, Kempton M, Rosenheck RA. Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int Clin Psychopharmacol 2013; 28: 57-66. 10. Tiihonen J, Haukka J, Taylor M et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 2011;168:603-9. 11. Kishimoto T, Nitta M, Borenstein M et al. Long acting injectable vs. oral anti- psychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. Presented at the 51st Annual Meeting of the American College of Neuropsy- chopharamacology, Hollywood, December 2012. 12. Barnett PG, Scott JY, Rosenheck RA. How do clinical trial participants compare to other patients with schizophrenia? Schizophr Res 2011;130:34-9. 13. Hoblyn J, Rosenheck RA, Leatherman S et al. Veteran subjects willingness to participate in schizophrenia clinical trials. Psychiatr Q 2013;84:209-18. 14. Leatherman S, Liang MH, Krystal JH et al. Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia. Submitted for publication. 15. Taylor DM, Young CL, Mace S et al. Early clinical experience with risperidone long-acting injection: a prospective, 6- month follow-up of 100 patients. J Clin Psychiatry 2004;65:1076-83. 16. Olfson M, Marcus SC, Ascher-Svanum H. Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone.